Extended Data Fig. 7: Immune checkpoint blockade treatment alters senescent population and ageing phenotypes in vivo.

a, The representative images of immunofluorescent staining in liver with IgG and αPD-1 treatments as shown in Fig. 4a. (Blue: DAPI; Red: PD-L1; Yellow: tdTomato; Green: F4/80) Scale bar: 500 μm b, The quantified proportion of F4/80^- in Tom⁺ cells from immunofluorescent staining sections of liver from mice with the indicating treatments. (IgG: n = 5, αPD-1: n = 6) c, The proportion of Tom⁺ cells in F4/80^- (left panel) and F4/80⁺ cells (right panel) from immunofluorescent staining sections as in b. (IgG: n = 5, αPD-1: n = 6) d, The proportion of PD-L1⁺ cells in Tom⁺/F4/80^- from immunofluorescent staining sections as in b. (IgG: n = 5, αPD-1: n = 6) e, The motor performance test of young (3-month-old) and old (17.5-month-old) wild type mice. The staying time was recorded from starting rotation of rotarod model to the mouse falling on the switch. (Young IgG: n = 6, Young αPD-1: n = 6, Old IgG: n = 7, Old αPD-1: n = 8) f, The grip strength test of mice as in e. (Young IgG: n = 6, Young αPD-1: n = 6, Old IgG: n = 7, Old αPD-1: n = 8) Data are presented as means ±SEM of three or more independent experiments. Unpaired two-sided t-test was performed (b, c, and d). Two-way ANOVA with Sidak’s test was performed (e and f). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The precise p-values were described in Methods.